Effect of concurrent intra-arterial infusion of platinum drugs for patients with stage III or IV uterine cervical cancer treated with radical radiation therapy.

Abstract

PURPOSE:

The purpose of this study was to explore the effect of concurrent intra-arterial infusion of platinum drugs in patients with stage III or IV uterine cervical cancer treated with radical radiation therapy.

PATIENTS AND METHODS:

Thirty-three patients with advanced (stage IIIA, 2; IIIB, 28; IVA, 3) uterine cervical squamous cell carcinoma were randomized into a concurrent intra-arterial infusion of platinum drugs with radiation therapy (IAPRT) group (18 patients) and a radiation therapy alone group (15 patients). After altering intrapelvic blood flow by embolization of the superior and inferior gluteal arteries under pelvic angiography, intra-arterial infusion of platinum drug through catheters inserted into both internal iliac arteries was performed concurrently with radiation therapy. One-shot infusion of cisplatin (100 mg/m2) twice with a 2- to 3-week interval was performed in eight patients, weekly infusion of carboplatin (100 mg/m2) via a reservoir five to six times was performed in four patients, and daily shot of cisplatin (10 mg/body) or 21 days via a reservoir was performed in six patients. Radiation therapy consisted of external-beam irradiation of 50 Gy/25 fractions/5 weeks for the whole pelvis with midline block after 30 Gy and intracavitary high-dose-rate brachytherapy using tandem and ovoids of 24 Gy/4 fractions/4 weeks to point A.

RESULTS:

The local complete response rate of the IAPRT group was 94% and was significantly higher than that of the radiation therapy group (67%). There were no significant differences in local response in the three drug delivery methods. Two- and 5-year overall survival rates were 54.5% and 44.4% in the IAPRT group, and 74.5% and 50.0% in the radiation therapy group, respectively. There was no significant difference between the two groups. In the IAPRT group, grade 3 or 4 acute bowel complications were seen in 33% of patients, grade 3 or 4 late bowel complications were seen 44%, and grade 3 or 4 myelosuppression was seen in 33%, and these complications were seen more in the IAPRT group than in the radiation therapy group and caused death in some patients.

CONCLUSIONS:

IAPRT had a better local response than radiation therapy but showed no proof of control over recurrence and had a poorer survival than radiation therapy. There were many local recurrences and distant metastases, contrary to the better first response of the IAPRT group over the radiation therapy group. Complications of the IAPRT group were very severe and made the patient's performance status and prognosis worse than in the radiation therapy group. We need to design some methods to decrease these complications to make use of the good local response acquired with IAPRT. Furthermore, we should re-examine the indication of IAPRT in patients with a large tumor because local recurrence and distant metastasis would be inevitable.

• Authors: H Onishi, M Yamaguchi, K Kuriyama, T Tsukamoto, K Ishigame, T Ichikawa, S Aoki, T Yoshikawa, T Araki, A Nambu, T Araki, A Hashi, T Yasumizu, K Hoshi, H Ito
• Journal: The cancer journal from Scientific American (Cancer J Sci Am) 2000 Jan-Feb Vol. 6 Issue 1 Pg. 40-5 ISSN: 1081-4442 [Print] United States
• PMID: 10696738 (Publication Type: Clinical Trial, Journal Article, Randomized Controlled Trial)

Topics

• Adenocarcinoma (drug therapy, mortality, pathology, radiotherapy)
• Adult
• Aged
• Aged, 80 and over
• Carcinoma, Squamous Cell (drug therapy, mortality, pathology, radiotherapy)
• Combined Modality Therapy
• Disease-Free Survival
• Embolization, Therapeutic
• Female
• Humans
• Infusions, Intra-Arterial
• Middle Aged
• Neoplasm Staging
• Survival Analysis
• Uterine Cervical Neoplasms (drug therapy, mortality, pathology, radiotherapy)